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EXECUTIVE SUMMARY
HIV disease progresses much more rapidly in children than in adults. Mortality begins to rise
in the first few weeks of life for HIV-positive infants not on ART. Infant HIV diagnosis as early as
possible in a child’s life followed by immediate ART could stem this progressive rise in infant
mortality, particularly as several studies have suggested that an increased proportion of perinatal
infections may occur in utero when maternal ART is received during pregnancy. This study,
“Assessing the Feasibility, Acceptability, and Costs of Diagnosing HIV at Birth in Lesotho and
Rwanda,” leverages two existing cohort studies to address some critical questions related to very
early infant diagnosis (VEID). The objective was to determine the feasibility, acceptability, and
costs associated with the addition of birth HIV testing to the routine testing algorithm for infants
born to HIV-positive women. Findings will contribute to the global guidance on whether current
early infant diagnosis (EID) guidelines should be reconsidered to add birth HIV testing as standard
of care.

METHODOLOGY
This study used a mixed methods design. Some existing data from two USAID-funded study
cohorts in Lesotho and Rwanda were extracted for this analysis: the Prevention of Mother-to-child
Transmission (PMTCT) Program Effectiveness among Women and Infants in Lesotho (PEA-WIL)
Study taking place in three EGPAF-supported districts (Thaba-Tseka, Butha-Buthe, and Mohale’s
Hoek) and the Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV
(Kabeho) Study. Birth DNA-PCR testing was added prospectively to the standard testing algorithm
at ages 6 and 14 weeks in Lesotho. Retrospective DNA-PCR testing of dried blood spot specimens
collected at or around the time of birth was performed in infants who participated in the Rwandan
study.
New qualitative and quantitative study activities were also conducted under this VEID study.
These include:
1. Semi-structured interviews with health workers (HWs), laboratory personnel, and a subset
of postpartum women from the PEA-WIL study in Lesotho. Interviews were conducted with
a total of 46 respondents from eight PEA-WIL facilities, five district laboratories, and the
National Reference Laboratory (NRL). Data were coded according to a standardized codebook
and analyzed according to the following themes: acceptability, feasibility, and retention and
treatment initiation.
2. Abstraction of HIV and testing-related data from mother-baby pairs and dates of specimen
and result transfer along the “EID pathway” from the parent study cohorts, PEA-WIL and nonPEA-WIL facilities, and the national EID database. Turnaround times (TAT) were calculated and
compared at study and non-study facilities for HIV-exposed infants receiving birth and six-week
DNA-PCR testing and for all HIV-positive study infants.
3. Interviews and record review of facility and laboratory costing data. Both direct (personnel,
consumables) and indirect (personnel, capital costs, maintenance and utilities) costs were
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collected retrospectively from January to December 2015 at eight PEA-WIL facilities and the
NRL. VEID unit cost, the additional cost of adding a test at birth, and the cost of identifying and
initiating one child on treatment were calculated. Costing data collection took place in Lesotho
only, though the unit cost from Lesotho was applied to the HIV transmission rate in Rwanda to
assess the potential costs of offering VEID services in the Rwandan context.

KEY FINDINGS
Qualitative findings on acceptability
Overall, birth testing was acceptable to women, health workers (HWs), and laboratory staff
participating in the in-depth interviews, with most recommending to roll out birth testing
nationally. The major benefit cited by women and HWs was earlier knowledge of the child’s
HIV status. Additional benefits cited by HWs included earlier initiation of treatment for positive
children resulting in a reduction in infant mortality, alleviation of caregiver uncertainty, and
earlier test results allowing guidance on proper care for the child by mothers and HWs. All lab
staff agreed that the primary benefit was early treatment initiation. Most women interviewed had
no negative perceptions of VEID and generally expressed satisfaction with how services were
delivered.

Qualitative findings on feasibility
HWs and laboratory staff reported that the DNA-PCR processing, transporting, and testing
processes were the same at birth as other testing time points, and that some fast-tracking
mechanisms were in place for positive test results, though these were not necessarily
standardized or formalized. Feasibility-related challenges revealed in the interviews were largely
reflective of the increased burden additional testing would have on existing shortcomings with the
early diagnosis system as a whole, such as workload and reagent stock-outs, particularly at the
central laboratory; problems with communication between facilities and laboratories; and delays
in the return of HIV test results. Other challenges, such as missed opportunities to perform a birth
test, could be attributed to the pilot nature of birth testing in the context of a study, which meant
some activities (e.g., group counseling on VEID) were not routinized and that testing was only
performed by study staff at facilities. Finally, the issue of home deliveries revealed weaknesses
with tracing children to ensure they were tested within two weeks of life.

Qualitative findings on infant retention and treatment initiation
Women and HWs did not indicate that birth testing affected subsequent infant HIV testing
acceptance or clinic attendance. HWs felt that clinic attendance would either not be impacted by
the timing of infant diagnosis or that women who have infants infected at birth would have better
attendance, given that they would be more highly motivated and need to return regularly for refills
and more frequent monitoring. Women did not indicate that the addition of a birth test negatively
influenced their motivations to attend standard clinic services. No respondents expressed a
challenge with early initiation of treatment, but only the perspective of HWs was captured, as all
women interviewed had HIV-negative children. HWs felt reactions did not vary among mothers

2 ■ Assessing the feasibility, acceptability, and costs of diagnosing HIV at birth in Lesotho and Rwanda

learning their child was positive at birth versus other time points.

VEID and EID turnaround times
Findings on TAT from the data abstraction activity supported the interview responses regarding
delays with specimen and results transfer. As expected, among infants at study facilities, those
tested at birth received their results more quickly (starting from date of birth), with a median
TAT of 74.5 days (IQR 47.5–100.0) compared to infants tested at six weeks, with a median of
103 days (IQR 92–116). At non-study facilities, the median TAT was 112 days (IQR 105–122) for
the 6-week test. The maximum TAT to caregiver receipt of results was 125 days (approximately
16–18 weeks from the time of the birth test), so there were children likely having blood drawn
again at a subsequent visit for their 6-week test without having yet received the results from the
birth test. As indicated in the interviews, infants with positive HIV results were fast-tracked. The
time from blood draw to ART initiation was 38 days for the 1 PEA-WIL study child identified as
infected at birth, 49.0 days for the 1 PEA-WIL study child identified as infected at 6 weeks, and
35.0 and 66.0 for the 2 non-PEA-WIL children identified as infected at 6 weeks in the VEID study
cohort. Overall, there were 11 HIV-positive infants in the PEA-WIL Study as of October 2016. The
time from date of blood draw to ART initiation for the PEA-WIL study infants identified as infected
at birth ranged from 35 to 62 days. Overall time from blood draw to ART initiation was 49 and
63 days for the 2 infants identified as infected at 6 weeks, 177 and 199 days for 2 out of the 3
infants identified as infected at 14 weeks, and 40 and 139 days for the 2 infants identified as
infected at 6 months.

Costing
The comprehensive unit cost per VEID test (including counseling, drawing, packing and
transporting samples, and performing the test at the NRL) in Lesotho was $40.50. One of 199
infants was identified as HIV-positive at birth in Lesotho in 2015 (0.5 percent in utero infection
rate) and 2 of 517 in Rwanda retrospectively in 2013 and 2014 (0.4 percent in utero infection
rate). Based on the data from the VEID pilot study in Lesotho and the Kabeho study in Rwanda,
the cost of identifying and initiating one infant on treatment was lower in Lesotho than in Rwanda:
$8,057 and $10,381, respectively. The country cost per child benefiting from VEID was driven
by the rate of in utero infection in children. For example, in Lesotho, costs ranged from $8,057
with a 0.5 percent in utero infection rate to $810 with a 5 percent in utero infection rate. Based
on 2015 data, if the VEID program were rolled out nationally in Lesotho, in one year, there could
have been as many as 37 HIV-positive infants who would have benefitted from VEID, and 8 deaths
would potentially have been averted due to the VEID services and early ART initiation. In Rwanda,
in one year, 22 infants would have benefitted from very early diagnosis and ART initiation, and 5
deaths would potentially have been averted.

CONCLUSION AND RECOMMENDATIONS
Should birth testing be implemented nationwide in Lesotho, findings from this study suggest that
women, health workers, and laboratory personnel would find this policy change acceptable. They
also indicated that subsequent infant HIV testing and postpartum clinic attendance would not
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be affected by adding birth testing to the diagnostic algorithm. However, this study illuminated
some challenges to the feasibility of this approach, particularly with regards to the time from HIV
testing to the return of test results and treatment initiation for HIV-positive infants. While infants
identified as infected at birth were initiated on treatment more quickly than those tested at six
weeks, the turnaround time was still long and varied between one and two months. In order to
reduce TAT, it may be less burdensome and costly to strengthen counseling, tracing, and testing
efforts around infant diagnosis beginning at six weeks of life rather than adding birth testing.
Decentralization of testing to the district level and use of point-of-care HIV diagnostic machines
might also permit more timely treatment initiation for infants identified as HIV-positive and thus
minimize HIV-associated morbidity and mortality. Decentralized testing, particularly with point-ofcare machines that non-laboratory clinic staff can be trained to operate, could also reduce the
burden to the health system when testing is conducted at a single national laboratory, though the
costs of this approach also need to be considered.
In terms of VEID cost, costs are lowest when the rate of in utero infection is high. As VEID
coverage increases, the number of infants benefiting from the service increases as well
as the number of early infant deaths averted. In situations where PMTCT programs are not
well-established and maternal ART use is low, and hence the risk of MTCT remains relatively
high, universal birth testing might be considered. In situations where PMTCT programs are
well-established and most women are on ART during pregnancy, and hence risk of MTCT is
low, a targeted testing program of infants at high risk of in utero infection (e.g., no maternal
antiretroviral therapy or less than four weeks of treatment during pregnancy) might be a costeffective way of implementing birth testing. However, a targeted program may be more complex
to implement on a national scale, which could result in high-risk infants not being identified and
hence missing birth testing; countries will need to consider both costs as well as implementation
feasibility in designing national programs.
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INTRODUCTION
Global efforts to prevent mother-to-child HIV transmission (PMTCT) have resulted in a 70 percent
decrease in new pediatric infections since 2000. Despite the scale up of PMTCT programs, almost
25 percent of HIV-positive pregnant women did not receive antiretroviral therapy (ART) in 2015,
and treatment drop-out rates among women who were pregnant and breastfeeding remained
high, leading to increased risk of transmission to their children (UNAIDS 2016). Moreover, there
is still a widespread need for family planning in many countries (UNAIDS 2016, Campbell et al.
2016). Thus, it can be anticipated that new pediatric HIV infections will continue to occur for many
years.
HIV disease progresses much more rapidly in children than in adults. Without ART, mortality is as
high as 68 percent by age two in infants with perinatal infection, with much of this risk occurring
within the first months of life (Newell et al. 2004, Marinda et al. 2007). Mortality begins to rise in
the first few weeks of life, with an early peak as high as 20–30 percent between 8 and 12 weeks
of age (Marinda et al. 2007, Marston et al. 2011, Bourne 2009). This rapid increase in mortality
is due to a progressive decline in CD4 cell count and rapid HIV disease progression observed in
young infants without ART (Violari et al. 2008, Innes et al. 2014).
Early infant HIV diagnosis (EID) is critical, as early ART initiation between ages 6 and 12 weeks
has been shown to dramatically reduce early infant mortality by 76 percent and decrease HIV
progression by 75 percent (Violari et al. 2008). However, a study of South African infants starting
ART at a median age of 8.4 weeks showed that 62 percent had advanced HIV disease (CD4 <25
percent or WHO Stage 3 or 4) before starting ART even at this very early age (Innes et al. 2014).
Thus, even earlier diagnosis, potentially in the first 48 hours of life, and immediate ART might be
desirable. Several studies suggest that an increased proportion of perinatal infections may occur
in utero when mothers are receiving antepartum ART, and hence can be detectable on day one of
life (Lillian et al. 2013, Magder et al. 2005).
The current World Health Organization (WHO)-recommended algorithm for EID includes initial viral
testing of HIV-exposed infants at age 4–6 weeks. However, in 2015, among the 21 Global Plan
countries in Africa, only half of exposed infants received an HIV test in the first two months of life.
Even in countries with higher EID coverage such as South Africa, due to delays between testing
and return of results (turnaround time [TAT]), as many as 50 percent of infants tested were either
not started on ART or were lost to follow-up (Smith et al. 2014). In many cases, by the time results
are returned, the infant has already died. Very early infant diagnosis (VEID) and immediate ART
have the potential to prevent decline in immunologic function and clinical deterioration, averting
the progressive rise in infant mortality within the first weeks to months of life. A recent analysis
from South Africa concluded that six weeks may no longer be the optimal age to diagnose
perinatal HIV infections, and recommended consideration of two early PCR tests (VEID at birth,
followed by a test at 10 weeks) as the ideal diagnostic algorithm (Lillian et al. 2014).
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While birth virologic testing appears to be an attractive intervention to reduce early HIV-related
mortality, there remain many questions about implementing this approach on a broad scale,
including the cost-effectiveness of adding another virologic test to the diagnostic algorithm.
The current study, Assessing the Feasibility, Acceptability, and Costs of Diagnosing HIV at Birth in
Lesotho and Rwanda, leverages two existing USAID- funded EGPAF studies to address some of
the questions related to VEID. In Lesotho, as part of a pilot evaluation, birth DNA-PCR testing was
added prospectively to the standard testing algorithm at age 6 and 14 weeks at 13 study facilities
in three districts. These facilities were participating in an observational prospective cohort study
evaluating the effectiveness of PMTCT service delivery, the PMTCT Effectiveness among Women
and Infants in Lesotho (PEA-WIL) study. In Rwanda, retrospective DNA-PCR testing of dried blood
spot (DBS) specimens collected at or around the time of birth was performed in infants who
participated in a study evaluating 24-month HIV-free survival in infants born to mothers receiving
ART, the Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV (Kabeho)
study. The goal of the current study was to utilize data from these two studies to evaluate the
feasibility, acceptability, test TAT, and costs associated with the addition of birth HIV testing to the
routine testing algorithm for infants born to HIV-positive women. The costing component was led
by the Avenir Health team with the support of the EGPAF teams in Lesotho and Rwanda.
With approximately 30 percent of women aged 15–49 years estimated to be HIV-positive in
Lesotho and nearly 4 percent in Rwanda, this study reflects both high and low HIV prevalence
settings (Lesotho MOH 2016, Rwanda MOH 2015). PMTCT services are integrated in almost all
antenatal facilities in both Lesotho and Rwanda. Both parent studies included a cohort of over
600 HIV-positive women. Children in the Kabeho study were born between April 2013 and April
2014 and the study was completed in August 2016. The last PEA-WIL delivery of an HIV-exposed
child took place in October 2016 and prospective follow up of the cohort is ongoing.
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METHODOLOGY
OBJECTIVES
The objectives of the VEID study were to determine the:
1. Feasibility of adding early infant diagnosis testing at birth to the HIV diagnostic algorithm for
infants born to HIV-positive women in selected facilities in Lesotho.
2. Acceptability of infant birth testing among health workers (HWs), laboratory personnel, and
HIV-positive women in selected facilities in Lesotho.
3. Age at initiation of ART in HIV-positive infants with and without the availability of birth testing
and the time from HIV diagnosis to ART initiation in selected facilities in Lesotho.
4. Unit cost per VEID test, the cost per early infection identified and initiated on treatment in
Lesotho and Rwanda, and the potential impact of VEID in terms of early infant deaths averted.

STUDY DESIGN
This study used a mixed methods design. Some existing data from the USAID-funded study
cohorts in Lesotho and Rwanda were extracted for this analysis. New qualitative and quantitative
study activities were also conducted under the VEID study. These three activities were: 1) Semistructured interviews with HWs, laboratory personnel, and a subset of PEA-WIL study women
(Lesotho only); 2) Abstraction of HIV and testing-related data from mother-infant pairs and dates
of specimen and result transfer along the “EID pathway” from the parent study cohorts, PEA-WIL
and non- PEA-WIL facilities, and the national EID database in Lesotho; and 3) Interviews and
record review of facility and laboratory costing data. Costing data collection took place in Lesotho
only, though the costing analysis included both countries. The VEID study did not introduce any
new interventions, because birth DNA-PCR testing (defined as testing at birth or within the first
two weeks of life) was already being conducted as part of the parent studies.

DATA COLLECTION METHODS
Data Collection Activity #1: Semi-structured interviews with HWs,
laboratory personnel, and a subset of PEA-WIL study women in Lesotho
Interviews were conducted to address objectives 1 and 2 on feasibility and acceptability of
VEID, respectively. Interviews took place in eight out of the 13 PEA-WIL study facilities. Study
facilities were located in Thaba-Tseka, Butha-Buthe, and Mohale’s Hoek districts in Lesotho,
representing the highlands, lowlands, and foothills regions, respectively. The subset of facilities
were purposively selected for the VEID Study to reflect level (hospital, health center), geographical
region (highlands, foothills, and lowlands), and public or private ownership (Table 1). Table 1 also
shows which data collection activities took place at which facilities.
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Table 1 PEA-WIL/VEID study facilities in Lesotho: Characteristics and data collection activities
District

Facility

Facility level

Public or private+
ownership

Interviews
(Activity #1)

Abstraction
(Activity #2)

Costing
(Activity #3)

St. Theresa

Health center

Private

X

X

X

Lephoi

Health center

Private

Paray

Hospital

Private

X*

St. James

Hospital

Private

X

X

X

St. Peters

Health center

Private

X

X

X

Butha Buthe

Hospital

Public

X

X

X

Seboche

Hospital

Private

X

X

X

St. Paul

Health center

Private

Mohale’s Hoek Tsepo
(Lowlands)
Ntsekhe

Health center

Private

X

X

X

Hospital

Public

X

X

X

Mootsinyane

Health center

Public

X

X

X

Mofumahali oa
Rosary

Health center

Private

Holy Cross

Health center

Private

Thaba Tseka
(Highlands)

Butha Buthe
(Foothills)

+

All private facilities were operated by Christian Health Association of Lesotho (CHAL).

*

Lab personnel only

Women were eligible for the study if they were enrolled as PEA-WIL study participants and
attending their 6-week or 14-week postpartum visit. However, any woman in the study with a
child who was diagnosed as HIV-positive at birth regardless of visit timing was also recruited. One
to four women’s interviews were conducted per facility. For women’s interviews, PEA-WIL study
nurses communicated with research assistants when eligible women were scheduled for their
visits so that they could travel to the respective districts to recruit potential study participants.
HWs were eligible for the study if they were working at a PEA-WIL study facility and involved in
some aspect of VEID. HWs were excluded if they did not have involvement in any aspect of VEID.
As birth testing was being piloted through the PEA-WIL study, only study nurses who performed all
VEID-related tasks, and lay counselors who often delivered test results to the mother/caregiver,
met this criteria. Clinic nurses were not eligible, as they were not involved in any aspect of VEID
during this pilot phase. One to four provider interviews were conducted per facility. Laboratory
staff were recruited for interviews if they were working in one of the study districts or study
hospitals or the Lesotho National Reference Laboratory (NRL), and responsible for performing
the tests. One staff member at each of the district laboratories and four NRL staff were enrolled.
Potential HWs and laboratory participants were sequentially recruited based on their availability
and days on which research assistants were present.
All interviews were conducted between March and July 2016 by research assistants trained in
human subjects protections, the study protocol, and qualitative methods. The duration of the
interviews was 30 minutes to 1 hour. Those involving PEA-WIL cohort women were conducted
in Sesotho while interviews with HWs and laboratory staff were conducted in English. Topics

8 ■ Assessing the feasibility, acceptability, and costs of diagnosing HIV at birth in Lesotho and Rwanda

included early testing and treatment acceptability, procedures (e.g., testing, preparing specimens,
returning results, ensuring treatment initiation), and processes for home deliveries and false
positive test results.

Data Collection Activity #2: Abstraction of HIV and testing-related data
from mother-infant pairs
Data were abstracted primarily in order to determine the timing of ART initiation for HIV-positive
infants with and without the availability of birth testing in Lesotho (objective 3). This activity also
served to compare whether or not TAT of receipt of results by the caregiver and/or ART initiation
differed between study and non-study facilities, as the study facilities may have benefited from
additional study-related support and attention compared to non-study facilities. After excluding
low volume and hard-to-reach facilities (as was done for PEA-WIL site selection) in the same three
study districts, the remaining ten EGPAF-supported non-study facilities were selected for inclusion
in the VEID study. Finally, the demographic and clinical profiles of all PEA-WIL and Kabeho study
women with HIV-positive children (at birth and other time points) were reviewed for any trends
that might reveal risk factors for those whose children were infected at birth. The two subactivities are described below:
a. Calculate TAT for ART initiation for HIV-positive infants and other interim steps along the VEID
pathway for HIV-exposed infants
All HIV-exposed infants in the subset of eight PEA-WIL facilities born between 12 January
(following MOH IRB approval of the VEID sub-study) and 16 June 2016, to allow for
approximately six months of data collection, were included for this activity. The one study
child infected at birth during this timeframe was tested at a study facility not included in the
subset; however, in order to have a comparison of TAT at birth versus six weeks, this child’s
information was included in the analysis. All children born to HIV-positive mothers who
received a 6-week DNA-PCR test at 10 selected non-PEA-WIL study facilities in the 3 study
districts during the same time period were also included. PEA-WIL children contributed data
for both their birth and six-week DNA-PCR tests. In order to construct TAT, dates for the time
of blood draw, specimen receipt and testing at NRL, result receipt at health facility, receipt of
result by caregiver, and ART initiation (if applicable) were either extracted from the national EID
database or PEA-WIL study database or abstracted from facility registers. Data were collected
by trained research assistants and members of the study coordination team using paperbased tools between July and September 2016. All completed data were reviewed by the study
coordinator before entry into an Access database.
b. Review demographic and clinical profiles of all women with HIV-positive children from the PEAWIL and Kabeho cohorts and calculate TAT for all HIV-positive children diagnosed by DNA-PCR
testing in Lesotho
All PEA-WIL and Kabeho mother-infant pairs were included if the child was diagnosed as HIVpositive at any testing time point. This includes all Kabeho pairs and any diagnoses among
PEA-WIL pairs up until October 2016. This activity was undertaken to help address the
question of whether or not selective birth testing would be appropriate based on maternal
factors such as HIV diagnosis timing, ART duration, adherence, and viral load results. These
and other data were extracted from the parent study databases. As not all PEA-WIL HIVpositive infants were captured in the activity described in (a) above, this exercise ensured that
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TAT was included for all infants diagnosed with DNA-PCR testing. The national EID database
and facility records were also utilized for this activity.

Data Collection Activity #3: Interviews and record review of facility and
laboratory costing data
This activity addressed objective 4 on determination of costs associated with the addition of a
birth test to the EID algorithm. Eight sites were purposively selected as described above. Data
collection tools were piloted at one health center in Mohale’s Hoek and at a district laboratory
in Thaba Tseka; neither of these facilities was included in the subset. Responses from the
pilot testing were documented and the data collection tools were subsequently revised and resubmitted by EGPAF for ethics approval.
Cost data from these eight facilities and from the NRL were collected retrospectively for the
January–December 2015 time period. Staff interviews were conducted with finance/account
officers, facility managers, and nurses involved in VEID at facilities and the laboratory staff
processing and performing the DNA-PCR test. Both direct (direct personnel, consumables) and
indirect (indirect personnel, capital costs, maintenance and utilities) costs were collected at the
eight study facilities as well as at the NRL. These figures do not include the costs of pediatric
treatment, PMTCT, training, external technical assistance, or VEID-associated research activities.
As stated above, no staff were specifically trained to perform VEID during the period covered in
this study (January to December 2015), given that staff were already trained to perform virologic
EID testing of infants. In most cases, interviewees were not willing to share any salary information.
Robust effort was made by the study team to obtain salary grades, which were used in lieu of the
exact salary.

ETHICAL REVIEW
This study was approved by the Ministry of Health Research and Ethics Committee and the
George Washington University Institutional Review Board (IRB) in Washington, DC. All study staff
involved in data collection received human subjects’ research ethics and training on the informed
consent process prior to being in contact with the participants. This study was submitted as an
amendment to the PEA-WIL Study.

DATA ANALYSIS
Data Collection Activity #1
Four research assistants (interviewers) simultaneously transcribed and translated any Sesotho
recordings into English in MS Word files in preparation for qualitative analysis. Subsets of
recordings were reviewed against the transcripts by study staff fluent in both English and Sesotho.
Transcripts were reviewed by the Co-Principal Investigator (Gill) as they were finalized. Translated
transcripts were imported into MAXqda (V10), a qualitative data analysis program. Data were
coded according to a standardized codebook by the same four research assistants. A small
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subset of transcripts were coded by multiple reviewers and questionable segments of coded text
were resolved among the coders or by the Co-PI. Data were analyzed according to the following
themes: acceptability, feasibility, and retention and treatment initiation. Data were reduced to
matrices, then textual summaries, with quotes identified to illustrate key or novel points.

Data Collection Activity #2
Total TAT from sample collection to caregiver result receipt or ART initiation for HIV-exposed and
positive infants, respectively, were calculated along with TAT for intermediate steps along the VEID
pathway. Descriptive statistics were calculated for all variables of interest using frequencies and
percentages for categorical variables and means (standard deviations) and medians (interquartile
ranges) for continuous variables. The data analysis was conducted using SAS/STAT software,
Version 9.4 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA).

Data Collection Activity #3
Two Excel spreadsheets were customized to calculate key outputs: the unit cost of providing VEID
in Lesotho, the cost associated with the addition of an HIV test at birth, and the cost per early
infection identified and treated. The 2015 average exchange rate applied was LSL12.77 per US
dollar1. Input costs shared with other services were allocated to the VEID program based on the
proportion of the number of VEID patients to the total number of patients seen at the facilities.
A costing exercise was not performed in Rwanda, but the unit cost from Lesotho was applied to
findings from the Kabeho study to assess the potential financial costs of offering VEID services in
Rwanda, a lower HIV prevalence country.

1

http://www.oanda.com/currency/average (2015)
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KEY FINDINGS
CHARACTERISTICS OF THE SEMI-STRUCTURED INTERVIEW
PARTICIPANTS
Semi-structured interviews were conducted with 20 HIV-positive women who were attending their
6-week (n=13) or 14-week (n=7) postnatal visit. Of the 13 women interviewed at 6 weeks, 5
had not yet received infant birth testing results. Of the 7 women interviewed at 14 weeks, 1 did
not receive a birth test for her child because the testing window was missed following a home
delivery; the other 6 women received their infants’ birth results. Seven infants had blood taken on
the day of birth, with the remaining tested a few days post-delivery or at the 7-day visit. All infants
had blood taken for a 6-week test and 4 women attending the 14-week visit received these
results. All test results were HIV-negative.
Seventeen HWs responsible for administering birth testing or delivering birth test results were
interviewed. Fourteen HWs were study nurses (two of whom were trained as midwives) and four
were counselors. Years of professional experience ranged from less than 1 year to 15 years,
with a median of 3 years (IQR 2–9). The start date for birth testing implementation varied in
their facilities, from June 2014 to February 2015. Five district laboratory staff and four central
laboratory staff were interviewed; five were lab technicians and four were lab technologists.

QUALITATIVE FINDINGS ON ACCEPTABILITY AND FEASIBLITY
This section presents key findings organized by the following themes: acceptability, service
retention and uptake, facility feasibility, and laboratory feasibility. Illustrative quotes can be found
in Appendix A.

Acceptability
Acceptability has been defined by this study using the constructs of perceived benefits and
challenges of early testing and treatment initiation, birth test refusals, and perspectives on
national policy recommendations, including selective (“high risk”) versus universal testing.

VEID benefits
Nearly all women interviewed stated they were happy to have their child tested or to know their
child’s HIV status at birth. The primary benefit cited by women and HWs was earlier knowledge of
child HIV status. HWs added that birth testing allowed them to initiate earlier treatment, reduce
infant mortality, alleviate caregiver uncertainty, and guide proper care. All lab staff agreed that
the primary benefit was early treatment initiation. Most women interviewed had no negative
perceptions of VEID.
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VEID challenges
While women thought it was important to have their children tested at birth, they still expressed
concerns about testing that were not specific to timing, but in regards to possible infant
transmission, except for two women who expressed discomfort over pricking their newborn to
obtain blood. Women, HWs, and lab staff cited TAT as a challenge for all DNA-PCR tests—one
woman in particular pointed out that her child was being tested again at six weeks, without yet
receiving the birth test results.
Nearly all lab respondents were concerned about the delays to TAT that would potentially result if
birth testing were implemented nationwide. One delay was related to the transportation system
for specimens and results. Since some clinics have set days for blood draws, and transportation
for routine services at facilities is typically Monday through Friday, lab staff worried that for those
women who deliver on a weekend or after hours, the sample could remain at the facility for 5–6
days before being picked up. One district respondent suggested the pick-up schedule should be
twice per week, which is already happening in some facilities. Another TAT-related concern for
the lab was the limited capacity of the machines, which can only run so many tests at one time.
Additional TAT challenges are listed in the next section.
Other challenges reported by HWs and lab staff included difficulty obtaining a sufficient blood
sample at birth and weak follow-up systems to capture women who deliver at home, whose
infants then may miss the opportunity to receive a birth test. HWs also described issues that
were reflective of the pilot nature of birth testing, which could be addressed if the algorithm
was updated in the national guidelines. These included lack of birth testing information in
standard facility registers and group counseling messages that omitted birth testing and failed to
emphasize the 7-day visit for infants not tested at birth. Other lab-specific concerns included staff
shortages, stock-outs (mostly at central level), and storage of additional samples at the NRL.
While HWs did not perceive a significant increase in resource burden as part of the pilot,
counselors and all lab staff felt if birth testing were rolled out there would be an increase in
workload, which could be addressed at the laboratory level by the addition of lab technologists, or
data clerks to assist with the registration and packaging of samples.

Birth test refusals
HWs reported that birth testing refusals were rare; those that encountered refusals said the
reasons were 1) fear of hurting newborn, 2) long waiting time for blood draw, and 3) fear of HIVpositive result. VEID acceptance was sometimes the result of extensive counseling as well as the
existing, trusting relationship between study nurse and patient.

National policy recommendations
HWs felt that birth testing was important and the majority recommended nationwide
implementation. Most HWs and lab staff recommended birth testing for all HIV-exposed children,
rather than selective “high risk” testing, reasoning that all HIV-positive women should be
considered high risk and it is not always possible to know who is adherent to treatment. While
one lab respondent was in favor of broader implementation, it was suggested that VEID rollout be
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staggered, starting with hospitals and then lower level facilities, in order to better understand the
extent of the added burden to the lab/health system and to plan accordingly.

Feasibility
Feasibility has been defined by this study as the procedures used for HIV birth testing during the
parent study and how well they were performed, including counseling on and understanding of
birth testing, specimen transfer and processing, relaying results (including TAT and fast-tracking
HIV-positive results), and addressing the issues surrounding home deliveries.

Counseling on and understanding of birth testing
Women seemed to have some difficulty in understanding what was meant by counseling during
the interviews. The majority of respondents described counseling in basic terms, that they were
told blood was drawn to determine if their child was infected with HIV, but few other details were
mentioned. According to the counseling experiences described by women, two had nurses try to
prepare them for whatever result was received, one woman received an explanation about how
the blood was to be drawn, another was counseled on the series of tests the infant would undergo
(though she could not recall this accurately), and finally one was told her child was being tested
for the purpose of the study. From the HWs perspective, approximately half said their counseling
included the importance of testing the child as soon as possible after birth, in order to initiate
treatment and in effect save the child if positive. Other HWs reported more general strategies
including the modes of transmission, testing algorithm, when to expect results, the logistics of
testing, and, in a few cases, what would happen if the child tests positive for HIV. Nurses and
counselors also talked about the importance of ensuring the woman felt it was her choice and
that permission was granted, but that women may need significant time to consider the test and
discuss it with their health care provider, particularly if they just gave birth.
According to HWs, the most frequently mentioned questions and concerns by women were what
to do if their child’s result was positive, when results could be expected, would the child be hurt
unnecessarily, and that the child was too young to have blood drawn. Only one woman said that
not all of her questions were answered. HWs generally felt as if their patients understood the
counseling on birth testing clearly. They pointed to the discussions held, questions asked, and
that women would even be the ones to remind nurses about testing at various time points as
evidence of their understanding.
A significant number of women described the time spent counseling as too short. Among these
women, the amount of time being counseled varied from 5 to 35 minutes. No counseling was
reported to take longer than an hour. If just focusing on the time it took to counsel on birth
testing immediately before the test, three HWs responded with a range of 5–20 minutes. When
estimating across ANC and delivery visits, HWs estimated anywhere between 15 to 60 minutes,
depending on the woman’s level of understanding and questions, with the majority of HWs
estimating closer to 15–30 minutes.
Almost all HWs indicated that women were prepared for birth testing since its purpose and
importance was conveyed in group education and explained during the consent process at study
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enrollment, and women received reminders about the infant testing schedule during follow-up
ANC visits. Most women also reported that they were made aware of birth testing during their
antenatal visits, and all women who were asked said that the information they received about
birth testing in ANC versus delivery was consistent. When women were asked about counseling
for subsequent DNA-PCR testing (at 6 or 14 weeks), approximately half of respondents reported
that they did not receive counseling before blood was drawn.

Specimen transfer and processing and relaying results
HWs and lab staff described the steps from blood draw through receipt of results back at the
facility. In general, infant blood collection involves pricking children on the heel or toe with a
lancet and then bringing the DBS filter paper to the foot so that blood can be filled neatly within
the five circles of the card. Collection of birth specimens was performed in the delivery ward
or postnatal room by PEA-WIL study nurses, who were also generally responsible for specimen
preparation and packaging and documentation. If the district lab and MCH clinic were located
on the same hospital campus, nurses would hand-deliver specimens to the district lab; for most
health centers, Riders for Health transported the specimens to the district labs using motorbikes.
District laboratories registered specimens and compiled with others before shipping to the NRL
via DHL (usually weekly), or sometimes by hospital vehicle. District laboratories did not perform
DNA-PCR testing. One respondent reported that the registration step was sometimes skipped. All
samples were supposed to be registered in the Laboratory Information System (LIS), which should
be linked to the NRL, but this feature was not functional at the time of interviewing.
At the NRL, patient/specimen information and results were logged into the LIS. Prior to
processing, the DBS samples were prepared manually. A series of quality control steps were
performed to ensure accuracy. The machine logged the time and date and created hard copy
printouts. A second person had to review the results before authorizing them. Printouts of
results were typically returned via DHL to district laboratories and then in turn by Riders to
health centers. Study nurses or HIV testing and counseling (HTC) counselors delivered results to
caregivers.
The frequency of specimen and result transport and the average TAT for some of these activities
are provided in Appendix B. There were some differences in responses among HWs and lab staff
at the same facility in terms of how often specimens were transferred to the district lab and
how often they were picked up to be taken to the NRL. Estimated TAT to receive results back at
the MCH clinic ranged from two weeks to three months at both health centers and hospitals.
Some respondents indicated that sometimes results were never received. The variability and
uncertainty made it difficult to know when to tell women when to return to pick their results; thus
HWs instructions varied as well (e.g., check every time at clinic, in one month, at next visit). Given
the expense and delay of transporting samples and results, multiple HWs and lab respondents
suggested machines to run the tests be placed in districts in order to bring EID services closer to
women. Other suggestions to reduce TAT for all DNA-PCR testing included:
• Communicate HIV-negative results to women via text messaging and include prevention
strategies for keeping their child negative.
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• Facilitate better communication between the NRL and MCH clinics by providing a phone at the
central lab so that documentation errors can be addressed more quickly, as emails are not
always checked and access to the internet is limited in some places.
• Call the MCH clinic immediately whenever there is a positive result or repair the SMS printers so
there is a paper trail for results.
• Ensure the LIS is working properly between the district and central laboratory levels so that
when results are returned, the district lab can simply send them along to clinics.
Nearly all facilities described how HWs attempt to fast-track HIV-positive results to the caregiver.
Once a positive result reaches the facility, the first step is typically for the nurse or counselor
to call the caregiver. As one nurse in a hospital put it, “all people in MCH who saw the results
that are positive, it’s their responsibility to call that lady.” If the caregiver cannot be reached by
phone, a community or village heath worker will conduct a home visit or look for the woman in
the surrounding villages and ask her to return to the health facility. A respondent at one hospital
indicated that s/he tried to get caregivers to the clinic within a day. Fast-tracking was contrasted
with what happens when there is a negative result, which is to wait until the woman attends
her regularly scheduled clinic visit, since they are coming in every 1–2 months anyway. Women
described this approach in their interviews as working well.
The HW-reported challenges with following up with women whose infants had an HIV-positive test
result included poor mobile network coverage, unavailable numbers, and reaching caregivers who
were not local. While there may be fast-tracking mechanisms on the part of facility staff, there
does not appear to be a formal fast-tracking mechanism once it is discovered that the result
is positive at district or central laboratory level, though lab staff from three hospitals reported
having walked over the paper result to the MCH clinic on its campus or calling the health center
if there is a positive result, rather than waiting for nurses or Riders to pick up results. However,
most communication is in the direction of the health facility to the lab (via the toll-free number)
when results have been delayed. The reason given for results not typically being relayed over the
phone is so that the results can be properly documented in the patient’s health booklet. One
respondent described an instance where a positive result was communicated via phone between
district lab and health facility, but the result was actually negative and the child was initiated on
ART unnecessarily.

Facility-level birth testing differences
HWs and lab respondents reported that there were not differences in the DNA-PCR testing
process that takes place at birth versus other time points. There were also no differences found
between birth and subsequent DNA-PCR testing with regards to TAT. The only distinction made
was a function of the study itself. PEA-WIL nurses were often the only cadre at the health facility
to draw birth specimens; at other time points, this may be done by HTC counselors. Given this,
several respondents recommended that all nurses and counselors be responsible for birth testing
and are afforded the proper training to do so.

Home delivery follow-up
As stated above, home deliveries were named as a birth testing challenge. Women may not
return to the facility within the two-week window to have their infant tested and systems needed

16 ■ Assessing the feasibility, acceptability, and costs of diagnosing HIV at birth in Lesotho and Rwanda

strengthening in order to follow up with women who deliver at home, in South Africa, or, in the
case of this pilot, deliver at a non-study facility, which did not offer birth testing. If rolled out
nationally, it was also felt that health education would need to be improved to help ensure
mothers deliver in health facility and birth DNA-PCR tests are not missed.
Nurses employed several different strategies to ensure a birth test was conducted, the most
common of which was use of village or community health workers to bring women and their
newborns to a health facility. Lay staff may accompany women who deliver at home to a health
facility, report such instances to the MCH clinic, or track these mother-baby pairs and bring
them in once a nurse has learned of the delivery. Other strategies included emphasizing the
importance of facility delivery, or in cases where home delivery could not be avoided, bringing the
child to the health facility as soon as possible, requesting that the nurse be notified in the case
of home delivery, and following up with women via phone around the time of their estimated date
of delivery. At one facility, the respondent said village chiefs were enlisted to help ensure HIVpositive women were able to travel to the hospital for delivery. Only at one facility did the nurse
say that the birth test is often missed if the woman delivers elsewhere. This is due to residing in a
remote area with a poor network that makes follow-up via phone difficult.

Retention
Retention and treatment initiation addresses the potential influences of very early infant
diagnosis on subsequent infant HIV testing and clinic attendance, reactions to a positive
diagnosis and treatment initiation, and any differences between birth and other time points.

Subsequent testing and clinic attendance
Women and HWs did not indicate that birth testing affected subsequent infant HIV testing
acceptance or clinic attendance. Those few HWs who encountered women who refused birth
testing at their health facility indicated that women still accepted subsequent infant tests and that
the birth DNA-PCR test was the only issue, reasoning that the underlying cause was insufficient
sensitization, since birth testing was only in a pilot phase. One exception was described in which
a woman’s child received a birth test (with a negative result), but did not return at 6 or 14 weeks
because the woman did not want to take ART for herself and was avoiding the clinic. HWs felt that
clinic attendance would either not be impacted by the timing of infant diagnosis or that women
who have infants infected at birth would have better attendance, given that they would be more
highly motivated and need to return regularly for refills and more frequent monitoring. Women
did not indicate that the addition of a birth test negatively influenced their motivations to attend
standard clinic services, citing the necessary postpartum care needed (e.g., immunizations, child
examinations, drug refills).

Very early infant diagnosis and treatment initiation
Nurses were responsible for actually initiating infants on ART, but HWs indicated that all staff
were responsible for ensuring that they were initiated on treatment as soon as possible (while
waiting for confirmatory testing), for infants infected at any age. No respondents expressed
a challenge with early initiation, but only the perspective of HWs was captured, as all women
interviewed had HIV-negative children. HWs described typical reactions of mother and caregivers
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upon learning their child was HIV-positive, such as guilt, sadness, and confusion. Nonetheless,
they reported mothers were consoled by the opportunity to save their child’s life through
treatment, though intensive counseling was often needed to help them understand the diagnosis
and implications of treatment. Reactions were not felt to vary between mothers learning their
child was infected at birth versus other time points; counseling and individual personalities were
more relevant with regards to treatment acceptability for children. The only difference that HWs
could foresee was that mothers would experience greater guilt if their child was found to be
infected at six weeks versus birth, since they felt mothers perceived more agency over the health
of their child after delivery.

DATA ABSTRACTION FINDINGS: DIAGNOSIS AND TREATMENT
TURNAROUND TIMES
Overall, all HIV-positive women enrolled in the PEA-WIL study delivered as of October 2016. Of
these 614 HIV-exposed infants born to 606 women, a birth test was not performed for 29 percent
of them (n=178). Nine mothers (1.5 percent) declined birth testing and 22 infants (4 percent)
died within the first hours or days of life. Other reasons included home delivery, delivery over a
weekend or other time without a study nurse on duty, delivery at a non-study facility, and failure
to perform the test by a study nurse. Only one was due to a test kit stock-out and one other was
because the nurse failed to obtain a sufficient specimen. When birth specimens were collected,
they were packaged and transferred according to the standard EID procedures described in the
above section.
The results in this section are presented by the two sub-activities as described in the methods.

Diagnosis TAT
One sub-activity was to calculate TAT for ART initiation for HIV-positive infants and other interim
steps along the VEID pathway for HIV-exposed infants. Table 2 presents all of the HIV-exposed
infants born between 12 January (following MOH IRB approval of the VEID study, received on 11
January) and 16 June 2016, to allow for approximately 6 months of data collection. The purpose
of this exercise was to determine TAT for DNA-PCR tests conducted at birth and six weeks among
study HIV-exposed and HIV-positive infants as well as compare the 6-week test TAT with non-study
facilities. There were 50 PEA-WIL infants from eight study facilities meeting this criteria, including
one identified as infected at 6 weeks, plus 1 infant identified as infected at birth (in another of the
study facilities). There were 88 infants from 10 non PEA-WIL facilities; 5 children were identified
as infected at 6 weeks, however, 1 child was excluded from the analysis as data on TAT could not
be verified from source documentation. There were significant gaps in data availability, with more
incomplete information at non-study facilities.
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0–78.0

8.0 (11.7)

47
6.0
(3.0–8.0)

8.0

0–26.0

7.0 (5.6)

30
6.0
(3.0–10.0)

—

2.0–64.0

9.5 (13.6)

24
4.5
(3.0–10.5)

From receipt
of specimen at
NRL to testing
at NRL

0–74.0

22.2 (16.0)

60
17
(10.5–30.0)

24.3 (16.3)

41
45.0
(43.0–48.0)

25
21.0
(14.0–28.0)

—

15.0–60.0

28.1 (13.7)

17
22.0
(19.0–34.0)

From blood
draw to receipt
at NRL

All PEA-WIL infants, N,
median time(IQR)

6-week DNA-PCR (PEA-WIL facilities)

5.0

4.6 (3.8)

All infants, mean time (SD)

HIV-positive infant (n=1)

35
4.0
(1.0–8.0)

All infants, N, median time
(IQR)

Birth (PEA-WIL facilities only)

Birth to blood
draw

87.0–114.0

101.0 (13.5)

3
102.0
(87.0–114.0)

72.0–199.0

117.5 (28.7)

35
112.0
(105.0–122.0)

102.0

62.0–182.0

105.3 (23.7)

35
103.0
(92.0–116.0)

43.0

32.0–125.0

73.5 (27.6)

36
74.5
(47.5–100.0)

Total TAT: birth
to receipt by
caregiver

0–10.0

5.0 (7.1)

2
5.0
(0–10.0)

0

0

From result
receipt by
caregiver to
treatment
initiation

112.0–114.0

113.0 (1.4)

2
113.0
(112.0–114.0)

102.0

43.0

Total TAT
(HIV+ infants
only): birth
to treatment
initiation

Table 2 Turnaround time (in days) for infants born and tested at PEA-WIL facilities at birth and six weeks and infants born at non PEA-WIL
facilities tested at six weeks

The data did not appear to be normally distributed; thus the median and interquartile range (IQR)
are presented. However, as the mean and median are considerably different, both are included in
the table. Median TAT from birth to caregiver result receipt was 74 days (IQR 47.5–100) for those
infants tested at birth (36/50 infants had this information available). Median TAT from birth to
caregiver result receipt was 103 days (IQR 92–116) for the PEA-WIL infants tested at 6 weeks
(n=35). Infants at non-PEA-WIL sites tested at 6 weeks with information available (n=35/88) had
a slightly longer median TAT of 112 days (IQR 105–122). There were few HIV-positive infants; the
TAT from birth to ART initiation was 43 days for the 1 infant identified as infected at birth, the TAT
for the 1 HIV-positive PEA-WIL infant identified at 6 weeks was 102 days, and there was a median
of 113 days (IQR 112–114) for 2/4 infants identified as infected at 6 weeks from non-PEA-WIL
facilities with information available. The time from HIV diagnosis (caregiver receipt of results) was
the same day for the PEA-WIL infant identified as infected at birth, the PEA-WIL infant identified
as infected at six weeks, and one non-PEA-WIL infant identified as infected at six weeks. The time
was 10 days for the only other non-PEA-WIL infant with information available.
TAT was also constructed from time of blood draw to caregiver receipt of results or ART initiation
to make a more direct comparison of TAT and to understand if the processes differed for birth
versus 6-week testing. At PEA-WIL facilities, TAT to caregiver receipt of results was slightly longer
at birth (69 days, IQR 47–95, n=29) versus 6 weeks (62.5 days, IQR 54–71.5, n=28) for all
infants. At non-PEA-WIL facilities, median TAT from blood draw to caregiver receipt of 6-week DNAPCR results was 70 days (IQR 42–77, n=35). The TAT to ART initiation for the one PEA-WIL study
child identified as infected at birth was 38 days. Children diagnosed at 6 weeks at PEA-WIL versus
non-PEA-WIL facilities had similar TAT: 49 days for the 1 HIV-positive PEA-WIL study child and a
median of 50.5 days (IQR 35–66) for the 2/4 non-PEA-WIL children.
Because this exercise yielded very few HIV-positive children contributing TAT outcomes, TAT were
also calculated for all PEA-WIL positive children (as of October 2016) regardless of when they
became infected (Appendix C). Median TAT was 55.5 days (IQR 40–139) for the 10/11 HIVpositive children with data available at blood draw and ART initiation. TAT from date of blood draw
to ART initiation for the PEA-WIL study infants identified as infected at birth ranged from 35 to 62
days. Overall TAT was 49 and 63 days for the 2 infants identified as infected at 6 weeks, 177 and
199 days for 2 out of the 3 infants identified as infected at 14 weeks, and 40 and 139 days for
the 2 infants identified as infected at 6 months.

Treatment TAT
Another sub-activity was to review demographic and clinical profiles of all women with positive
children from the PEA-WIL and Kabeho cohorts and calculate TAT for all HIV-positive children
diagnosed by DNA-PCR testing in Lesotho.
Appendix D presents selected demographic and clinical characteristics of HIV-positive women
and their positive infants in Lesotho (n=11). Three HIV-positive infants died—two from respiratory
infections and one from malnutrition. One of these infants was diagnosed with HIV from birth
testing, initiated on ART at 6 weeks, and died at approximately 14 weeks of age from a respiratory
infection. In total, 8 out of the 11 women were not on ART at first ANC visit, 3 of whom had a child
infected at birth. Of these 8, their gestational age at first ANC visit ranged from 4 to 32 weeks.
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Eight of the women (3 with children identified as infected at birth) had maternal viral load results
at study enrollment in ANC, all of which were >1,000 copies/ml.
Appendix E presents selected demographic and clinical characteristics of HIV-positive women
and their positive infants in Rwanda. 92 percent (n=545/595) of live born infants, excluding
those who died within 2 hours of birth, had blood drawn and stored for a birth test. 95 percent
(n=517/545) had retrospective DNA-PCR testing performed. Two infants were infected at birth.
Six out of 512 infants born to HIV-positive women who were still enrolled in the study by the
end of the 24-month study follow-up period were diagnosed as HIV-positive. All six HIV-positive
children in Rwanda were initiated on treatment and none of the six HIV-positive children died.
Those women whose children were infected at birth had the shortest duration between study
enrollment and HIV diagnosis and ART initiation. Four out of the 5 mothers with a viral load test
at study enrollment had a result of >1,000 copies/ml, including those with the 2 infants with
infection present at birth.

COSTS ASSOCIATED WITH VEID
In 2015, 199 infants received a VEID test from the 8 facilities included in the VEID costing
exercise in Lesotho, while 287 VEID tests were performed at the NRL. (The PEA-WIL study
included five other facilities that were performing birth testing, but were not included in the
costing assessment.) Test results indicated that only one out of 199 (0.5 percent) VEID costing
study infants was found to be HIV-positive on birth testing and was initiated on antiretroviral
treatment.
The unit cost of VEID services (including counseling, drawing, packing and transporting samples,
and performing the test at the NRL) was determined to be $40.50. Major cost drivers were
supplies and commodities (46 percent), clinical labor (22 percent), construction cost/rental value
of the facilities (17 percent), sample transportation cost (11 percent), support staff (3 percent),
and equipment (1 percent).

Lesotho
In order to assess the potential impact of nationally scaling up VEID in Lesotho, the following
additional assessment was performed. In 2015, 11,744 children were born to HIV-positive
mothers in Lesotho and approximately 11,157 births (assuming no multiple births) were covered
by Lesotho’s PMTCT program intervention. At the 8 PEA-WIL study facilities that were included in
the costing analysis, 66 percent (199/300) of PEA-WIL infants born at these facilities in 2015
received a VEID test. Reasons for non-performance in the remaining 34 percent were identified
in the preceding section. If we assume that at minimum, a national program might test a similar
proportion of HIV-exposed infants at birth, then nationally 7,401 HIV-exposed children would
receive birth testing. Out of the 199 infants, 1 was found HIV-positive and initiated on treatment
(0.5 percent in utero infection rate).Thus, using a conservative estimate based on 66 percent
coverage nationally with VEID and an in utero infection rate of 0.5 percent, 37 HIV-positive
infants would have been identified as infected at birth and benefited from this service if VEID was
offered nationally in 2015, and the total incremental cost of adding a VEID test at birth would
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have been $299,618 ($40.50 per recipient times 7,401 children tested at birth). Thus dividing
the incremental cost by the number of beneficiaries (37) yields $8,057 as the cost per child
benefiting from VEID. This same result is obtained by simply multiplying the VEID unit cost by the
total number of infants who received the test during the pilot phase ($40.50 times 199). Using an
estimate of 21 percent2 mortality by age two months in children with peripartum infection without
antiretroviral therapy (Becquet 2012), a national VEID program with immediate initiation of ART
would theoretically have averted eight early deaths among infants.

Rwanda
VEID testing was assessed retrospectively in Rwanda using 2013/2014 data. Out of 595 HIVexposed newborn infants, 517 VEID samples, representing 87 percent (517/595) of infants,
were successfully processed, and two (0.4 percent) infants were found to be HIV-positive at birth.
National data from 2011–2015 were used to project the expected impact VEID could have had
on pediatric HIV in Rwanda. Using 87 percent VEID national coverage estimated from coverage
from the Rwanda Kabeho study and 0.4 percent in utero HIV infection rate, 22 HIV-positive
infants would have been identified as infected at birth and benefited from this intervention, which
theoretically could have averted five early deaths if VEID if immediate initiation of treatment was
offered nationally during the study period. Since the estimation of the unit cost of providing VEID
in Lesotho by this study is the first of its kind, this information was used to project the expected
cost per child benefiting from VEID in Rwanda during the study period, which would have been
$10,381.

Sensitivity Analysis
Considering that some of the reasons that VEID tests were not conducted were due to birth
testing implementation only as a part of the PEA-WIL study (including delivery at non-study
facility and absence of a study nurse at the facility), it is uncertain what the coverage would be
if this service was scaled up nationally. For this reason, VEID coverage varied from a pessimistic
value of 50 percent to a very ambitious target of 100 percent coverage. The rate of in utero HIV
infection also varied from 0.5 to 5 percent in Lesotho. The rate of in utero infection in the Rwanda
Kabeho study was lower than in Lesotho (0.4 percent versus 0.5 percent); thus the rate of in
utero infection for this exercise varied from 0.4 to 3 percent.

Based on the estimated number of births to HIV-positive women in 2015 in Lesotho and
Rwanda, Tables 3 and 4 provide costs outcomes of various scenarios where VEID coverage
and the percentage of infants diagnosed HIV-positive at birth were varied as noted above. It
is important to note that the rate of in utero infection does not affect the cost of diagnosis
(VEID unit cost), but does affect the cost per child identified. Thus, as the rate of in utero
infection increases, the cost per HIV-positive child identified at birth decreases. Also, VEID
coverage impacts both the number of infants benefiting from the intervention as well as the
number of early infant deaths averted, but not the cost per infant benefiting from VEID (Tables 3 and 4).

2

18-month post-infection mortality risks in the absence of treatment is about 60 percent, which translates to a
conservative estimate of about 21 percent in the first two months of life.
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Table 3 Cost outcome of VEID in Lesotho in 2015
VEID
coverage
50%
60%
63.3%
70%
80%
90%
100%

% of infants diagnosed
HIV+ at birth

0.5%

1%

2%

3%

4%

5%

6

12

23

35

47

59

28

56

112

167

223

279

7

14

28

42

56

70

Infants benefiting from VEID

34

67

134

201

268

335

Deaths averted

8

16

31

47

62

78

Infants benefiting from VEID

37

74

148

222

296

370

Deaths averted

8

16

33

49

66

82

Infants benefiting from VEID

39

78

156

234

312

390

Deaths averted

9

19

37

56

75

94

Infants benefiting from VEID

45

89

179

268

357

446

Deaths averted

11

21

42

63

84

105

Infants benefiting from VEID

50

100

201

301

402

502

Deaths averted

12

23

47

70

94

117

Infants benefiting from VEID

56

112

223

335

446

558

$8,057

$4,049

$2,024

$1,350

$1,012

$810

0.4%

1%

1.5%

2%

2.5%

3%

Deaths averted

3

7

10

14

17

21

Infants benefiting from VEID

13

33

50

66

83

99

Deaths averted

3

8

12

17

21

25

Infants benefiting from VEID

15

40

60

79

99

119

Deaths averted

4

10

15

19

24

29

Infants benefiting from VEID

18

46

69

93

116

139

Deaths averted

4

11

17

22

28

33

Infants benefiting from VEID

20

53

79

106

132

159

Deaths averted

5

12

18

24

30

36

Infants benefiting from VEID

22

57

86

115

144

173

Deaths averted

5

12

19

25

31

37

Infants benefiting from VEID

23

60

89

119

149

179

Deaths averted

5

14

21

28

35

42

Infants benefiting from VEID

26

66

99

132

165

198

$10,465

$4,049

$2,699

$2,024

$1,619

$1,350

Deaths averted
Infants benefiting from VEID
Deaths averted

Cost per infant benefiting
from VEID

Table 4 Cost outcome of VEID in Rwanda in 2015
VEID
coverage
50%
60%
70%
80%
87%
90%
100%

% of infants diagnosed
HIV+ at birth

Cost per infant benefiting from
VEID
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Sensitivity analysis results indicated that VEID cost per HIV-positive child identified at birth is
lower when the risk of in utero infection is high. Since the observed rate of in utero infection in the
Rwanda Kabeho study (0.4 percent) was lower than in the Lesotho PEA-WIL study (0.5 percent),
using these infection rates, the estimated cost per HIV-positive child was higher in Rwanda than
Lesotho ($10,465 versus $8,057, respectively). However, should the in utero infection rate be the
same in the two countries, the cost per HIV-positive infant identified would be the same (i.e., if
the in utero infection rate was 1 percent in both countries, the cost per child benefitting would be
$4,049 in both countries).
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DISCUSSION
Overall, birth testing was acceptable to respondents participating in the in-depth interviews, with
most recommending the roll out of birth testing nationally and universally and nearly all women
reporting they were happy to have their child tested or to know their child’s HIV status at birth.
However, the feasibility of the approach was called into question. Many HWs and lab respondents
identified challenges reflective of additional burdens to the larger shortcomings with the EID
system, such as workload and reagent stock-outs, particularly at the NRL, poor communication
between facilities and laboratories, and delays in the return of HIV test results; women also
raised the latter as a concern. Some challenges were also due simply to the pilot nature of birth
testing, which meant procedures were not routinized and there was limited involvement from
clinic staff. VEID-specific challenges included concern regarding obtaining blood from a newly
delivered child, which was noted rarely, some concerns from health workers and lab staff over
obtaining a sufficient and quality sample, and the potential for missed birth testing opportunities
when women deliver at home. What appears most important for birth testing to be successful are
strengthened follow-up systems for women not delivering at a health facility, early and intensive
counseling so women understand the continuum of DNA-PCR testing, and improvements to steps
along the EID pathway, specifically concerning specimen transfer and delivery of results.
One of the main challenges with birth testing was ensuring that a child was tested at birth or as
soon as possible thereafter. While the pilot nature of birth testing limited the number of children
who were tested, since birth testing only took place in study facilities and primarily only was
performed by study nurses, this experience does offer some lessons learned for what activities
should accompany a national rollout. This includes updating group counseling messages that HIV
testing will begin at birth and not six weeks and to emphasize the importance of mother-infant
pairs’ attendance at the seven-day visit, particularly if women deliver at home or in South Africa
rather than Lesotho. Awareness-raising outside the clinic settings so that HIV-positive women will
anticipate an infant birth test may also contribute to acceptance of early testing.
Given that the Lesotho Demographic and Health Survey found that nearly a quarter of women
delivered at home (Lesotho MOH 2016), the potential for missing the birth test window is
considerable. Having a standard 7-day postnatal visit in Lesotho helped to capture women whose
infants could not be tested at delivery, even though HWs admitted this visit was not adhered to
as well as the six-week visit. While attendance may still be limited due to the proximity of the visit
to delivery, adding a DNA-PCR test by two weeks of age (the definition of birth testing used in
this study) to the algorithm could improve adherence to this visit. The importance of this visit to
capture some birth tests which may have been missed otherwise also raises the question of what
happens in other countries in which a 7-day visit is not standard.
Some of the women interviewed perceived counseling on HIV birth testing to be limited. There
was also a disconnect between the counseling descriptions provided by women and the more
in-depth ones provided by health workers interviewed, which could be recall bias or reflect
shortcomings with the counseling itself. Women also noted that counseling on subsequent HIV
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tests was minimal. What was similar across both participant groups was that counseling on HIV
birth testing took place at ANC visits as well as around the time of delivery. This was likely due
to the fact that PEA-WIL study women had already given consent and birth testing was included
as one of the activities about which they were informed before they agreed to join the study.
HWs also said that women may have been concerned about birth testing or infant HIV testing in
general, but that intensive counseling was needed for some women to understand its importance.
As above, counseling on birth testing, how it fits into the EID testing algorithm and the importance
of all DNA-PCR testing needs to be conveyed at every opportunity with women, potentially starting
in the community or at the time of ANC group education.
As expected, the TAT from birth to caregiver receipt of results was shorter for PEA-WIL infants
tested at birth versus 6 weeks (74 vs. 103 days). Among the HIV-positive PEA-WIL infants, the TAT
from birth to ART initiation was also shorter for the infant infected at birth versus 6 weeks (43 vs.
102 days).
When comparing TAT from blood draw to caregiver receipt of results between birth and
subsequent tests, a clear picture does not emerge. Among PEA-WIL infants born between January
and June 2016, TAT to caregiver receipt of results was slightly longer at birth (67.5 days) versus
six weeks (62.5 days). When examining only PEA-WIL positive infants, there is a somewhat linear
trend toward increased TAT with increasing child age. However, all HWs and laboratory staff
reported that the DNA-PCR processing, transporting, and testing processes were the same at
birth and six weeks, and this TAT only captures two infants. This may be related to fewer visits to
the clinic for immunizations and MCH follow-up at later ages. TAT from blood draw to caregiver
receipt of results was a week longer at non-PEA-WIL facilities among all infants; when comparing
the HIV-positive infants’ time to treatment initiation, these were fairly similar. This suggests PEAWIL infants may have benefited from the extra support afforded in the study, but only slightly.
There was evidence of fast-tracking HIV-positive results, with shorter TAT from blood draw to
caregiver receipt of results: 55.5 days for HIV-positive infants at all time points versus 67.5
days and 62.5 for birth and 6 weeks tests, respectively. This is consistent with the qualitative
findings, which describe some fast-tracking mechanisms, though not necessarily standardized or
formalized. All four infants infected at birth initiated ART within six to nine weeks of age, likely at
their six week visit. However, because the maximum TAT to caregiver receipt of results was 125
days (approximately 16–18 weeks from the time of the birth test), there would have been children
having blood drawn again at subsequent visits without yet having received birth test results.
Differences aside, TAT was still found to be long and largely unchanged from the study conducted
on TAT in Lesotho five years ago (Gill et al. 2013). While the respondents interviewed at the
clinic, district lab, and central lab level all have clearly defined roles in the EID pathway, they
are distinct and separate from each other, to the point that respondents could really only speak
about their responsibilities and supposed the bottlenecks were happening at another level. The
most effective solution to the transport challenges identified may be point-of-care machines to
bring EID services closer to clients. Rollout of five point-of-care HIV testing machines supported
by UNITAID in Lesotho (including one study district) is anticipated for the end of 2016 (EGPAF
communication). Since the transportation of samples and some of the related challenges are
unavoidable, other potential solutions could involve more efficient ways of delivering results—
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through a functional LIS system between central and district labs, repairing and putting back into
use SMS printers, or changes to the current communication flow that would allow for central and
district lab staff to initiate communication of results to facilities.
Different strategies (no EID, testing once at birth, once at six weeks, and testing twice at birth and
six weeks) were modeled as part of a study in South Africa (Francke et al. 2016). For their base
case scenario, they used a lower cost per test than we identified through the costing exercise in
Lesotho ($25 compared to $40.50, respectively) and projected a 1.8 percent in utero infection
rate (compared to the 0.5 percent we observed in PEA-WIL in Lesotho). They reported that EID
testing twice at birth and six weeks improved outcomes and was cost-effective compared to EID
at six weeks alone in South Africa. The incremental cost-effectiveness ratio (ICER) was $2,900/
year of life saved, 45 percent of South Africa’s per capita gross domestic product (GDP) (an ICER
of <50 percent of GDP is considered cost-effective). The ICER became >50 percent GDP if: ARTassociated reductions in mortality/OI risk was <78 percent, test specificity was <98 percent or
sensitivity <30 percent, linkage to ART was <15 percent, result-return was <16 percent, PMTCT
coverage was >97 percent, test costs exceeded $31, mean TAT was >3 months or clinical care
costs were >1.3 times base values. Given >95 percent PMTCT coverage in Lesotho with an in
utero transmission rate of 0.5 percent and a per test cost of $40.50, testing at birth and 6 weeks
may not be cost-effective in the Lesotho context. In this situation, strengthening the 6-week
testing system and improving TAT is another viable option for improving outcomes for HIV-positive
infants.
Based on various scenarios, VEID followed by immediate ART could annually avert between 8
and 117 early infant deaths in Lesotho, and between 7 and 69 in Rwanda, with the cost per child
benefiting from VEID ranging from $810 to $8,057. The percentage of children who are identified
as HIV-positive at birth does not affect the cost of diagnosis, but does affect the cost per HIVpositive child identified with VEID. Thus, as the in utero infection rate among newborns increases,
the cost per HIV-positive child identified decreases. Also, VEID coverage impacts the number of
infants benefiting from the intervention as well as the number of early infant deaths averted, but
not on the cost per HIV-positive infant benefiting from VEID.

LIMITATIONS
This study has some limitations which are noted below. More details on the costing component
limitations are provided in Appendix F.
1. Semi-structured interviews: Only a small number of women were interviewed on their
infant HIV birth testing perspectives and no women who had a child infected at birth were
interviewed, despite efforts to include them. Also, no interviews were conducted with clinic
(non-study) nurses. These nurses were not involved in VEID as it was only in the pilot phase,
though they may have viewed VEID less favorably. While they would certainly be involved if
VEID were rolled out nationally, clinic counselors, who were interviewed as part of this study,
would be primarily responsible for performing infant HIV counseling and testing.
2. Data abstraction: This exercise yielded relatively few HIV-positive infants diagnosed at
different time points, making it difficult to discern whether the variability observed is actual
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or due to the small sample size. Also, some of these data were abstracted from existing
facility records which were at times incomplete and could not always be linked to the
national EID database.
3. Costing:
a. Personnel: Average salary was applied to the corresponding personnel category in all the
study sites.
b. Effects of recall bias: No time-motion study was carried out to assess how staff spent their
time on VEID activities.
c. VEID unit cost: VEID unit cost from Lesotho may not necessarily be representative of the
unit cost in Rwanda.
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CONCLUSION AND
RECOMMENDATIONS
CONCLUSIONS
Based on the qualitative findings, women, health workers, and laboratory personnel were in favor
of expanding EID to birth, recognizing the importance of identifying and treating HIV-positive
infants as early as possible. However, respondents also clearly outlined a number of challenges
with the overall EID system, many of which were not specific to birth testing but would be
exacerbated by the burden of an additional birth testing time point. These included stock-outs,
lab staffing shortages, and unreliable or infrequent transportation of samples and results. These
challenges help to explain the TAT of nearly two months for PEA-WIL children tested at all ages
in the study thus far. Children diagnosed with HIV at birth were getting on treatment earlier than
under the standard testing algorithm, but still not as quickly as hoped. If there was a stronger
system in place a more compelling case could be made for birth testing.
It is beyond the scope of this study, given the small numbers of HIV-positive children and relatively
few facilities implementing birth testing, to make a recommendation regarding birth testing
for Lesotho or other similar settings. While this study demonstrated acceptability, it does raise
questions about feasibility, namely those related to TAT, but also missed opportunities to test at
birth and limited follow-up systems to ensure infants are tested within the first two weeks of life.
Counseling, tracing, and testing efforts could be better focused on strengthening infant diagnosis
beginning at six weeks of life rather than the addition of birth testing. More national investment
to get shorter TAT at six weeks would also likely be less burdensome on the clinic and laboratory
network. For instance, the shortest step in the VEID/EID pathway at study and non-study facilities
was from receipt of specimen at the NRL to testing at the NRL. If the specimen reached the NRL,
a test would be performed relatively quickly. However, this study highlighted the challenge of
transferring specimens and returning results to caregivers expeditiously. Respondents offered
several recommendations comparatively less expensive than birth testing, such as ensuring SMS
printers and the LIS system are functioning properly and establishing communication from the
laboratory to the clinic, to minimize TAT and the potential for lost samples and results.
However, another factor to consider is the anticipated rollout of POC HIV diagnostic testing
machines in Lesotho, Rwanda, and elsewhere in sub-Saharan Africa. The addition of these
machines would help to address challenges related to transportation of samples and results
(including lost samples), lab staff shortages by task shifting of testing, and the limited capacity of
a small number of machines at central level. Point-of-care HIV diagnostic testing machines would
likely make birth testing more feasible, though this may also be an expensive option. Moreover, in
a hub and spoke model, in which lower level facilities (“spokes”) send EID samples for processing
at select hospitals (called “hubs”), there are still opportunities for delayed transfer of specimens
or results.
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VEID resulted in 1 child out of 199 (0.5 percent) in 2015 found HIV-positive at birth in the Lesotho
PEA-WIL study and initiated on treatment, while 2 of 517 (0.4 percent) were found HIV-positive at
birth retrospectively in the Kabeho study in Rwanda. The unit cost of VEID was $40.50. Because
the rate of in utero infection was higher in Lesotho than Rwanda, the estimated cost for VEID
per HIV-positive child identified was lower in Lesotho than in Rwanda, respectively $8,057 and
$10,381. Sensitivity analysis was performed on the two key parameters driving these costs—VEID
coverage and the rate of in utero HIV infection among newborns.

RECOMMENDATIONS
Should birth testing be implemented nationwide in Lesotho, findings from this study suggest that
women, health workers, and laboratory personnel would find this policy change acceptable. They
also indicate that subsequent infant HIV testing and postpartum clinic attendance would not be
affected by adding birth testing to the diagnostic algorithm. However, this study illuminated some
challenges with the feasibility of this approach, particularly with regards to the time from HIV
testing to the return of test results and treatment initiation for HIV-positive infants. While infants
infected at birth were initiated on treatment more quickly than those tested at six weeks, the
turnaround time was still long and varied between one and two months. In order to ensure timely
treatment initiation for HIV-positive infants and minimize associated morbidity and mortality, VEID
costs, and burden to the health system, testing at a singular national laboratory should also be
compared to the implications of implementing other strategies to minimize turnaround times,
such as strengthening the current system of the initial infant test at six weeks.
Respondents were in favor of universal testing for HIV-exposed infants, rather than selective
testing for those born to HIV-positive women considered high risk. A review of the demographic
and clinical profiles of study women with HIV-positive children revealed that most women had high
viral load at enrollment regardless of the timing of infant infection. However, Kabeho study women
whose children were infected at birth were more likely to have shorter duration of ART prior to
delivery. There was not a consistent pattern in terms of risk factors, but statistical significance
could not be established due to small numbers. A more in-depth investigation should explore the
association between birth infection rate and women’s risk factors.
Results from this study indicate that provision of VEID nationally could have potentially averted
eight early deaths with about 37 infants identified as HIV-positive at birth benefiting from early
treatment in Lesotho, and five early deaths averted with 22 infants identified as HIV-positive at
birth benefiting from early treatment in Rwanda during a one year study period. If VEID coverage
increases, the number of infants benefiting from the service increases as well as the number of
early infant deaths averted. The cost per child benefiting from VEID is driven by the rate of in utero
HIV infection, and this could range from $810 with 5 percent in utero infection rate to $8,057
with 0.5 percent in utero infection rate in Lesotho. Thus, costs are lowest when the risk of in utero
infection is high. In situations where PMTCT programs are not well-established and maternal ART
use is low, and hence the risk of MTCT remains relatively high, universal birth testing might be
considered. In situations where PMTCT programs are well-established and most women are on
ART during or even before pregnancy, and hence risk of MTCT is low, a targeted testing program
of infants at high risk of in utero infection (e.g., no maternal antiretroviral therapy or <4 weeks of
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treatment during pregnancy) might be a cost-effective way of implementing birth testing. However,
a targeted program may be more complex to implement on a national scale, which could result
in high-risk infants not being identified and hence missing birth testing; countries will need to
consider both cost as well as implementation feasibility in designing national programs.
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APPENDIX A
ILLUSTRATIVE QUOTES BY THEMATIC AREA OF WOMEN,
HEALTH CARE PROVIDERS, AND LABORATORY PERSONNEL
WHO PARTICIPATED IN IN-DEPTH INTERVIEWS
Response

Illustrative quote

Acceptability
VEID benefits

…it’s like, most of the time you will find that you’re interested to know your child’s status at birth
when you are HIV-positive, you would like to know immediately after birth your child’s status…and
you will have a good feeling when your child gets tested because you will be able to know their HIV
status…. (Woman)
I think it actually helps us in earlier identification of infected children rather than waiting for 6
weeks and then from 6 weeks waiting for results is going to take around 4 weeks, that is, when
you are going to realize that the infant is infected. But with the birth DNA I think mostly at 6 weeks
the results will be back. So I think we can actually initiate the child earlier than when we wait for 6
weeks. (Counselor, Hospital)

VEID benefits/
challenges

…but birth testing they feel that their children are still very young to be punctured and for the blood
to be drawn from them…. Sometimes they feel that it is unnecessary whereas some feel that it
is necessary because during labor some of them are frightened, there is still that mindset that
says there is a possibility that a child may get infected and that birth testing alleviates their fear,
knowing that at least I will know the results of birth as soon as possible rather than waiting for 6
weeks. (Nurse, HC)

VEID challenges

If I find that [results] are not available, but have to draw her blood again yet I still do not know her
status, stresses me, wondering what the condition might be, yes! (Woman)
There are going to be more samples and that is going to affect turn-around time…because I think
at national level there is going to be high workload and it means processing a lot of samples—we
are going to get the results later than we get them now. (District lab)
This birth DNA-PCR, if it were a national thing, it will mean when we do health education, we would
include it and we would also mobilize in the community…It would mean these mothers would know
to come for a 7 day visit and would also mean that mothers would know that their children are
tested at birth. (Nurse, Hospital)
[Workload] would be very very high but in return we would be getting something very big for the
country, sort of a victory. So you know sometimes to work for something important like that is really
beneficial. (District lab)

Birth test refusals

It’s just that they need patience maybe, so …when she refuses, you say no she is refusing and then
you go… but if you talk to them and then try to tell them, and then try to show them the importance
of doing DBS at birth, they understand at the end, they do. (Nurse, HC)
…what I realized is that most parents do not want to find their children infected so they want to do
whatever it takes to…know the status of their children. (Counselor, Hospital)

Perspectives on
national policy
recommendations

…Because we always talk about the four prongs of HIV infection…If we say there could be HIV
infection during labor, what are we doing about it, this is the perfect thing that we should do about
it, we should test babies at birth. (Nurse, HC)
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Feasibility
Counseling on
and understanding
of birth testing

I think it was because even before she said anything, I told her that before I left home for testing I
had already counseled myself. I told myself that this is my life and I have to do the right thing to live
and in the case of my baby as well I knew that I was supposed to do the right thing. (Woman, 14week visit)
…labor comes with emotions as women suffer many illnesses, post-natal depression or anything
so at that time we have to understand that it might not mean she actually [refuses] but she might
need some rest [after delivery]. So what I do is that I explain thoroughly to mothers “you know this
is what needs to happen, the positives and the negatives…but I understand if you need time for
me to explain further,” and after explaining, they gave me their go-ahead and not because I forced
them, [but] because I still reassure them that “I respect your opinion, it is you who will give me the
go ahead and if you say no, I cannot do it.” (Nurse, HC)

Specimen transfer
and processing
and relaying
results (TAT)

Turnaround times for all the results are the same because sometimes you might even find out that
you have drawn this DNA-PCR at birth and at 6 weeks and then you get the one for 6 weeks and
the one for birth has not yet arrived. (Nurse, Hospital)
…when it’s beyond two months, we then develop a doubt whether we will ever get them. We call
NRL and ask where the results are. Sometimes they say they have never received such, then I
would not know what had happened, but we would have drawn them within two weeks or two
months.... (Nurse, Hospital)
[When they reach the lab do you have any knowledge of how long they spend before going to the
central lab?] I really don’t know how long they take because we often find them still piled there
when we bring other specimens. (Counselor, Hospital)

Specimen transfer
and processing
and relaying
results (Fasttracking positive
results)

We get the results after I think a month, a month and 2 weeks, a month or so. I think if the results
are positive we find ways of contacting the mother but if it’s negative she will be told when coming
to the next visit at the clinic…when it’s positive if we have got the numbers we call, we also have
people in the communities who track such people immediately, such people are brought to the
facility so that the infants would be initiated. (Counselor, Hospital)
All people in MCH who saw the results that are positive, it’s their responsibility to call that lady.
(Nurse, Hospital)

Home delivery
follow-up

We always have an appointment for an estimated date of delivery for them so if that date
approaches then we call them just to inquire if they have delivered because not all of them deliver
here so we need to call them just to be sure where they are. If they are in this facility then it means
maternity will inform us if such a delivery is there. (Counselor, Hospital)
[Do they come here when they are 6 weeks only or 7 days?] …sometimes they complain the place
is too far, no mode of transport, they struggle truly. You may find that a woman after delivering at 7
days, they are not yet fit to travel such long distance, it is truly very far. (Counselor, Hospital)

36 ■ Assessing the feasibility, acceptability, and costs of diagnosing HIV at birth in Lesotho and Rwanda

Retention and treatment
Subsequent
testing and clinic
attendance

It is because the first time she was tested the infection was not detected, so it might be visible
when she is growing up, so it is important to keep testing her. (Woman, 6-week visit)
Well I think those children who were infected at birth, the caregivers usually ensure that they come
for services regularly…but for those who actually might get HIV-positive results later…what I‘ve
realized is that…the caregivers don’t always come because they know that the child only comes for
a prophylaxis not a lifelong treatment. Yah, so they just tend to miss appointments because they
don’t have any particular service they come for except for prophylaxis. (Counselor, Hospital)

Very early Infant
diagnosis and
treatment
initiation

A person is going to be scared, confused, and is going to be angry. But the other hand…if they know
at an earlier stage they will say at least my child will get treatment early enough...as compared to
knowing at a later stage when the child could even be at a worse stage. (Counselor, HC)
They will react the same way because at that time they will see the benefits of performing the
test earlier if they were taught well enough the benefits of knowing the status earlier then I think
it would help them know that even if the child if infected, there is still time, there is hope that the
child can still live a healthy better life, the earlier it is detected, the earlier you can get treatment
and live happily ever after. (Nurse, HC)
It does not matter if the child is infected at birth or at 6 weeks or even at 12 months, 12 years. The
reaction is still going to be the same. (Nurse, Hospital)
I think the one at 6 weeks…should have a lot of guilt because I think she would think maybe I did
something wrong, I did not do as they say, I should take care of the baby, as compared to that one
at birth because that one at birth might think maybe something went wrong during pregnancy or at
birth.... (Nurse, Hospital)
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Twice/week

Once/week
(More often
if needed)

HC 2
(HW=1)

HC 3
(HW=2)

HC 4
(HW=2)

Every day

HC 1
(HW=2)

Health centers (HC)

Frequency
of blood
draws

2 days

1 day

Time from
blood draw →
packaging for
district lab

Once/week

Twice/week,
unless raining

Twice/week

Once/week,
unless raining
Twice/week

Frequency
of sample
transport
from clinic →
district lab

Sample transport
from district lab
→ NRL (frequency
and/or average
time)

Twice/week

Takes 3 days

Twice/week

Result transport
from district →
clinic (frequency
and/or average
time)

2 weeks–2
months, can
be as long
as 6 months
2–3 months

3 weeks

1 month

2+ months
1 month

Overall TAT
back to
facility

Samples used to
be sent twice/week
but changed due to
limited laboratory
capacity

Used to be 6 weeks
TAT

Pick-up days same
days as blood draws

Only 1 HIV+PCR since
started working at HF;
initiated on treatment
after 5 days following
receipt of results

Comments

APPENDIX B
SPECIMEN TRANSFER FROM FACILITIES AND TAT:
RESPONSES FROM HWS AND LABORATORY PERSONNEL
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Once or twice/
week

Once/week

If DHL does not come,
samples will go with
EGPAF’s vehicle

+/- 6 weeks
4–6 weeks

Once/week

1 month

Since TAT varies, tell
women to always pass
by HTC room to check
for results

6 weeks–3
months

Note: Lab respondents estimated from 3 days to 2 weeks to conduct testing and generate results at the central lab, but with the stock-outs or equipment breakdowns, it might
take 2–3 months for results.

Hospital
5
(Lab=1)

1–2 days

If beyond 2 months,
likely won’t ever
receive result (see
quote)
If district car happens
to be transporting
patients to Maseru,
it will pass by MCH to
see if any specimens
are ready
2–8 weeks
4–6 weeks
6–8 weeks
2–3 months

Takes 1–2 weeks,
but sometimes 1–3
months
Takes 2 weeks
Don’t know
Pick-up is once/
week

Takes 8 days
Pick-up is once/
week

Once/week

Once/week,
free to take any
day
Twice/week

Doesn’t wait for
results to accumulate
in MCH clinic since the
return of other results
can be followed up
when visiting the
district lab

+/- 4 weeks,
but some
results never
arrive
6 weeks

Takes 2–3 days

Hospital
4 (HW=3,
Lab=1)

2–3 days
1–2 days, but
as short as 3
hours to dry

Once/week
(More often if
needed)

Don’t know
Pick-up is once/
week

Everyday

2–3 days

Hospital
3 (HW=1,
Lab=1)

Hospital
2 (HW=4,
Lab=1)

Hospital
1 (HW=3)

Hospitals

—

—

21

Infant 2

Infant 3

Infant 4

33

Infant 6

8

22

Infant 8

Infant 9
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9, 6.0
(2.0–8.0)
4.9 (3.4)
0–9.0

19

9, 21.0
(13.0–22.0)

18.7 (9.4)

3.0–33.0

Infant
11

N, median
time (IQR)

Mean
time (SD)

Range

—Data not available

9

13

8

3

1

7

6

8

0

—

—

2

From receipt
of specimen at
NRL to testing
at NRL

Infant
10

Infection at 6 months

3

Infant 7

Infection at 14 weeks

28

Infant 5

Infection at 6 weeks

21

Infant 1

Infection at birth

From date of
blood draw to
receipt at NRL

8.0–165.0

44.6 (64.8)

9, 13.0
(11.0–16.0)

13

16

165

11

152

8

8

16

—

—

12

From testing at
NRL to result
receipt at
health facility

0–21.0

7.0 (7.0)

11, 4.0
(3.0–9.0)

21

3

9

9

3

3

5

1

19

4

0

From result
receipt at
health facility
to receipt by
caregiver

0–77.0

11.1 (23.8)

10, 0.5
(0–12.0)

77

0

0

—

12

13

0

0

8

1

0

From result
receipt by
caregiver to
treatment
initiation

29.0–199.0

69.8 (56.9)

11, 49.0
(38.0–62.0)

62

40

199

29

165

50

49

38

40

61

35

Total TAT: from
blood draw
to caregiver
receipt

35.0–199.0

85.0 (62.2)

10, 55.5
(40.0–139.0)

139

40

199

—

177

63

49

38

48

62

35

Total TAT: from
blood draw to
ART initiation

APPENDIX C
TAT (IN DAYS) FOR PEA-WIL CHILDREN INFECTED WITH HIV
SINCE START OF STUDY TESTED VIA DNA-PCR

APPENDIX D
SELECTED DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
OF HIV-POSITIVE WOMEN AND THEIR INFECTED INFANTS IN
LESOTHO (N=11)
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1.4
6.4
ABC/3TC/
LPV/r
13.7

Age at infant HIV
diagnosis (weeks)

Age at infant ART
initiation (weeks)

Infant ART regimen

Age of infant death
(if applicable)

ABC/3TC/
LPV/r

8.9

0

AZT/3TC/
NVP

7.0

0.1

No

2.9

No

Facility

TDF/3TC/
EFV

None

—

—

No

0

0

Never
married

Some
primary

29

25–29

ABC/3TC/
LPV/r

6.1

0.7

—

2.8

No

Facility

TDF/3TC/
EFV

None

—

642,000

No

0

0

Never
married

Some
secondary

18

<20
18
Some
primary
Married
0

0
No
—
428,054
None
TDF/3TC/
EFV
Facility
No
3.5
No
6.1
15.1
ABC/3TC/
LPV/r

Completed
primary
Married
0.5

0.5
Yes
875,410
—
None
TDF/3TC/
EFV
Facility
No
3.5
No
14.6
14.6
ABC/3TC/
LPV/r

30+

24

20–24

Child infection at 6
weeks

ABC/3TC

26.4

17.7

No

3.2

No

Facility

TDF/3TC/
EFV

None

—

13,960

No

0.9

0.9

Never
married

Completed
primary

32

20–24

20.9

ABC/3TC/
LPV/r

—

17.0

No

—

No

En route to
facility

AZT/3TC/
NVP

None

—

71,537

Yes

29.1

30.1

Married

Some
secondary

18

20–24

ABC/3TC/
LPV/r

30.7

14.7

No

2.4

Yes

Home

TDF/3TC/
EFV

None

189,000

—

No

2.0

2.0

Married

Completed
primary

19

20–24

Child infection at 14 weeks

—

42.9

23.0

No

—

No

Home

TDF/3TC/
EFV

None

—

132,297

No

0

2.6

Married

Some
primary

21

20–24

49.9

ABC/3TC/
LPV/r

36.3

30.6

Yes

2.9

No

Facility

TDF/3TC/
EFV

None

—

159,242

No

0

0

Married

Some
primary

15

20–24

Child infection at 6 months

—Data not available.

The number of missed doses (maternal adherence) and maternal ART regimen is provided for the visit at which infection was detected. For instance, the delivery information is included for infants
who were infected at birth and 6 weeks (maternal information was not collected at the 6-week visit).

*

No

No

3.6

2.4

Infant birthweight

Facility

Infant hospitalized prior to
diagnosis

Facility

Home or facility delivery?

TDF/3TC/
EFV

No

TDF/3TC/
EFV

Maternal ART regimen*

None

80

85,785

No

1.1

1.1

Living with
partner

Completed
secondary

4

20–24

No

None

Maternal ART doses
missed (7-day recall)*

Premature delivery?

36,881

Maternal viral load at
delivery

Yes

On ART at first ANC visit?
40,429

31.0

ART duration at study
enrollment (months)

Maternal viral load at
enrollment

31.9

Married

Some
secondary

21

20–24

Time from HIV diagnosis
to study enrollment
(months)

Marital status

Educational level

Gestational age at first
ANC (weeks)

Maternal age at
enrollment

Child infection at birth

Some primary
Living with
partner
—
26.1
Yes
272,000
3,640
23,600
None
TDF/3TC/EFV
Facility
No
3.5
No
6.0
28.1
ABC/3TC/ LPV/r

Educational level

Marital status

Time since HIV diagnosis
(months)

ART duration at
enrollment (months)

On ART at first ANC visit?

Maternal viral load at
ANC enrollment visit

Maternal viral load at
delivery

Maternal viral load at 24
months

Maternal ART doses
missed (3-day recall)*

Maternal ART regimen*

Home or facility delivery?

Premature delivery?

Infant birthweight (kg)

Infant hospitalized prior
to diagnosis

Age at infant HIV
diagnosis (weeks)

Age at infant ART
initiation (weeks)

Infant ART regimen

ABC/3TC/ LPV/r

16.4

6.0

No

3.5

No

Facility

TDF/3TC/EFV

None

—

34,700

2,000

Yes

1.7

1.7

Living with
partner

Some primary

20–24

Yes

ABC/3TC/ LPV/r

41.7

7.4, 38.6**

No

3.0

No

Facility

TDF/3TC/EFV

None

Undetectable

558

2,350

Yes

1.3

1.3

Never married

Never attended
school

<20

Yes
30+
Completed
primary
Living with
partner
32.5
32.5
Yes
577
—
7,220
—
TDF/3TC/NVP
Facility
No
3.6
No
42.1
42.3
ABC/3TC/ LPV/r

Completed
primary
Living with
partner
13.5
2.5
No
—
12,100
Early termination
from study
None
TDF/3TC/EFV
Facility
No
3.7
No
42.9
48.7
ABC/3TC/ LPV/r

No

20–24

No

Child infection at 9 months

—

—

111.0

No

3.0

No

Home

TDF/3TC/EFV

None

172,000

290,000

202,000

Yes

88.8

124.8

Living with
partner

Some primary

25–29

No

Child infection
at 24 months
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Ages reflect the first and fourth DNA-PCR tests, which were positive. Two interim test results were negative.

—Data not available.

**

The number of missed doses (maternal adherence) and maternal ART regimen is provided for the visit at which infection was detected. For instance, the delivery
information is included for infants who were infected at birth

*

25–29

No

Maternal age at
enrollment

Infection present at
birth?

Child infection at 6 weeks

APPENDIX E
SELECTED DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
OF HIV-POSITIVE WOMEN AND THEIR INFECTED INFANTS IN
RWANDA (N=6)

APPENDIX F
COSTING: FACILITY AND LABORATORY SURVEYS
Facility and laboratory-based costing included interviews with key personnel at eight PEA-WIL
sites across three EGPAF-supported districts in Lesotho: Thaba-Tseka, Butha-Buthe, Mohale’s
Hoek, and in Maseru where the NRL is located. At each facility, information was collected from
clinical and support staff. Clinical or direct staff members comprised nurses, HTC counselors, and
laboratory personnel. Support or indirect staff members included individuals who were generally
not working directly on the VEID program. This included, for example, data clerks, accountants,
maintenance staff, security guards, facility managers, office assistants, and receptionists.
Information on personnel employment status (permanent or contracted) was collected for both
direct and indirect staff members. Additional information collected included the number of
personnel, their salaries, and the level of effort or percentage of time expended on VEID services.
The data indicated that no volunteer provides support to VEID services in the eight facilities
surveyed.

Equipment and Furniture
Interviewees were asked to provide a list and count of all equipment and furniture utilized in
the counseling area and laboratory or offices where the VEID samples are collected/processed.
Facilities generally were not able to estimate the percentage of time that an item of equipment or
furniture was used for VEID, and therefore the research team estimated this percentage based on
the patient volume for VEID versus other services.

Vehicles and VEID Samples Transportation
VEID samples are transported by two courier services: Riders for Health (R4H) from health
centers to district hospitals/labs—they also pick up results from district labs to health centers—
and by DHL from district facilities to the NRL and vice-versa. The costs of transporting VEID
samples were obtained respectively from R4H annual report (Riders for Health 2012) and from
the DHL office in Maseru. It is important to note that DHL provides transport services from the
following district to the NRL (and collect results from the NRL to the district facilities): Thaba
Tseka (St James Hospital), Butha Buthe (Butha Buthe and Seboche Hospitals), and Mohale’s
Hoek (Ntshekhe Hospital). Because these companies are contracted to transport EID samples,
the cost of transporting EID or VEID samples is a fixed cost

Utilities
The costing of utilities was allocated based on the space used for VEID relative to the space of
the entire facility. Costs related to the rental or construction value of the facility were also similarly
apportioned to the EID and VEID program based on the number of patients seen. However, the
NRL construction value was not available, and thus it was assumed that the value of the facility
was equivalent in rental terms to that of a median, “typical” facility in Lesotho. Because of limited
data on property prices and rental market in Lesotho, the 2012 subsidized factory rental rates
from the Lesotho National Development Corporation (LNDC) was used. In this case, the rental
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value of the facility was determined to be LSL41 per square meter (IMF 2012). This includes the
average cost of rental (LSL8.5) and the average economic return to cover the initial capital costs
and ongoing maintenance (LSL32.5).

Cost Data
Both direct (direct personnel, consumables) and indirect (indirect personnel, capital costs,
maintenance and utilities) costs were collected at the eight study facilities as well as at the NRL.
There was no cost associated with training to perform EID services because staff were already
trained to perform EID services.

Limitations
• Personnel: Personnel (clinical and support staff) costs were often not available at the facility
level. Robust efforts were made to obtain salary grades, with the average applied—to the
corresponding personnel category—and across all the eight facilities; this approach could have
potentially led to over- or under-estimation of both clinical and support staff wages.
• Effects of recall bias: No time-motion study was carried out to assess how staff spent their time
on VEID activities. Instead, respondents were asked to provide their level of effort which could
lead to effect of recall bias. The information obtained (which was based on recall and not on
actual observations) was insufficient to be used for allocative purposes. Instead, an allocation
method was developed, using the proportion of EID and VEID clients relative to the total client
volume at the facility to apportion indirect staff time to VEID. It is therefore possible that there
may have been an overestimation or underestimation of time spent on VEID in Lesotho.
• Utilities: Mootsinyane did not report any utility costs. Indeed, the following utilities were not
available in some of the surveyed facilities:
• Water—James, St Theresa, St Peters, Tsepo, and Mootsinyane
• Electricity—St Theresa, St Peters, Butha Buthe, and Mootsinyane
• Construction year/rental value: Construction cost of the NRL was not available and there were
limited data on property prices and rental market in Lesotho. Thus, its equivalent rental value
was estimated to that of a “typical” facility using the 2012 subsidized factory rental rates from
the Lesotho National Development Corporation (IMF 2012).
• VEID unit cost: Lesotho is a lower middle income country while Rwanda is a low income country.
Thus, the VEID unit cost from Lesotho may not necessarily be a full representation of VEID unit
cost in Rwanda.
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